Wist u dat uw browser verouderd is?

Om de best mogelijke gebruikerservaring van onze website te krijgen raden wij u aan om uw browser te upgraden naar een nieuwere versie of een andere browser. Klik op de upgrade button om naar de download pagina te gaan.

Upgrade hier uw browser
Ga verder op eigen risico
Allround in APIs and services

News

29 July 2025

Ofichem expands drug substance capabilities with acquisition of Meribel Pharma Solutions’ Uppsala site in Sweden

Read more
09 July 2025

Ofichem acquires Avivia B.V. to expand formulation development capabilities

Read more
23 September 2024

Ofichem will support the IPCEI Med4Cure project as associated partner

Read more
22 August 2024

White paper: Development and production of orphan drugs. Tailored solutions by Lab Ofichem

Development and production of orphan drugs. Tailored solutions by Lab Ofichem
Read more
12 March 2024

Whitepaper: Accelerating drug development using 505(b)(2) regulatory pathways

Accelerating drug development using 505(b)(2) regulatory pathways
Read more
23 January 2023

Drug manufacturer InnoGenerics acquired.

Drug manufacturer InnoGenerics acquired by the Ofichem Group.
Read more
29 July 2022

Is the market still growing?

The outlook of CDMO for active pharmaceutical ingredients (APIs): Is the market still growing?
Read more
16 May 2022

Ofidit and Rephine: Partners in Business

The mutually-beneficial alliance will see the deeply-experienced global GMP auditors assume responsibility for Ofidit’s third-party audit service and stock its audit reports in its extensive library
Read more
29 September 2021

Feestelijke opening nieuwe R&D faciliteit en QC laboratorium

Read more
20 July 2021

Ofipharma/Ofichem secures the Netherlands with extra Propofol supply

Ofipharma and Ofichem have managed to bring in additional stock of Propofol ampoules to the Netherlands. Propofol is an essential anaesthetic in the ventilation of COVID-19 patients.
Read more
20 July 2021

Building of new R&D pilot plant started

Our colleagues in China recently moved in their new office.
Read more
Load more